Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease

High-mobility group protein box 1 (HMGB1) is a member of a highly conserved high-mobility group protein present in all cell types.HMGB1 plays multiple roles both inside and outside the cell, depending on its subcellular localization, context, and post-translational modifications.HMGB1 is also associated with the progression of various diseases.Particularly, HMGB1 plays a critical role in CKD progression and prognosis.HMGB1 participates in multiple key events in CKD progression by activating downstream signals, including renal inflammation, the onset of persistent fibrosis, renal aging, AKI-to-CKD transition, and important cardiovascular complications.More importantly, HMGB1 plays a distinct role in the chronic pathophysiology of kidney disease, which differs from that in acute lesions.This review describes the regulatory role of HMGB1 in renal homeostasis and summarizes how HMGB1 affects CKD progression and prognosis.Finally, some promising therapeutic strategies for the targeted inhibition of HMGB1 in improving CKD are summarized.Although the application of HMGB1 as a therapeutic target in CKD faces some challenges, a more in-depth understanding of the intracellular and extracellular regulatory mechanisms of HMGB1 that underly the occurrence and progression of CKD might render HMGB1 an attractive therapeutic target for CKD.